Predictors of immunotherapy benefit in Merkel cell carcinoma

Merkel cell carcinoma is a rare cancer for which immune checkpoint blockade is standard-of-care for recurrent/metastatic disease. However, not all patients benefit from immunotherapy. A greater understanding of molecular mechanisms and predictive biomarkers are unmet needs. We retrospectively analyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Kacew, Alec J., Dharaneeswaran, Harita, Starrett, Gabriel J., Thakuria, Manisha, LeBoeuf, Nicole R., Silk, Ann W., DeCaprio, James A., Hanna, Glenn J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720777/
https://www.ncbi.nlm.nih.gov/pubmed/33315984
http://dx.doi.org/10.18632/oncotarget.27823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720777/
https://www.ncbi.nlm.nih.gov/pubmed/33315984
http://dx.doi.org/10.18632/oncotarget.27823

Ejemplares similares